Liquid Chromatographic Approach for Analysis of Favipiravir–A Repurpose Drug for COVID-19

Favipiravir is a potential repurpose moiety to treat COVID-19 by depletion of virus load in infectious patients. To analyze and separate Favipiravir with remarkable effi ciency, X-Bridge C8 column (150 x 4.6 mm, 5 μ) and a solvent phase of 0.1% TEA and acetonitrile (40:60 v/v) with 1-mL/min fl ow rate were used. The eluted favipiravir and possible degradants were detected at 225 nm. Further, the process was validated by using ICH (Q2R1) guidelines to ensure the method’s suitability in the pharmaceutical sector. The RT of Favipiravir was observed at 3.7 min with good linearity of 2 to 30 μg/mL. %RSD of both system and method precision was assessed in the series of 0.32 to 0.98. The mean percentage recovery of Favipiravir was in the range of 99.0–100.4%. The limit of detection (LoD) and limit of quantifi cation (LoQ) were assessed to be 0.024 and 0.084 μg/mL for favipiravir. The outcomes confi rmed that the projected approach was economical, insightful, simple and precise with better sensitivity. Investigation of Favipiravir in the incidence of a variety of stressed or forced degradation environments ensures stability indicating quality of the developed approach